Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014 (2014), Article ID 509027, 8 pages
http://dx.doi.org/10.1155/2014/509027
Research Article

High Expression of Ecto-Nucleotidases CD39 and CD73 in Human Endometrial Tumors

1Departament de Patologia i Terapèutica Experimental, Facultat de Medicina, Campus de Bellvitge, Universitat de Barcelona, Pavelló de Govern, 4a Planta, Lab. 4145, C/Feixa Llarga s/n, 08907 L’Hospitalet de Llobregat, Barcelona, Spain
2Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain
3Servei d’Anatomia Patològica, Hospital de Bellvitge, Barcelona, Spain
4Servei de Ginecologia, Hospital de Bellvitge, Barcelona, Spain

Received 19 November 2013; Revised 25 December 2013; Accepted 8 January 2014; Published 24 February 2014

Academic Editor: Graça Ferreira-Dias

Copyright © 2014 Elisabet Aliagas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Blay, T. D. White, and D. W. Hoskin, “The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine,” Cancer Research, vol. 57, no. 13, pp. 2602–2605, 1997. View at Google Scholar · View at Scopus
  2. M. V. Sitkovsky, J. Kjaergaard, D. Lukashev, and A. Ohta, “Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia,” Clinical Cancer Research, vol. 14, no. 19, pp. 5947–5952, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. C. Becker, M. H. Andersen, D. Schrama, and P. T. Straten, “Immune-suppressive properties of the tumor microenvironment,” Cancer Immunology, Immunotherapy, vol. 62, no. 7, pp. 1137–1148, 2013. View at Publisher · View at Google Scholar
  4. S. Merighi, P. Mirandola, K. Varani et al., “A glance at adenosine receptors: novel target for antitumor therapy,” Pharmacology & Therapeutics, vol. 100, no. 1, pp. 31–48, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Zhou, X. Zhi, T. Zhou et al., “Overexpression of ecto-5′-nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix,” Cancer Biology & Therapy, vol. 6, no. 3, pp. 426–431, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Ghiringhelli, M. Bruchard, F. Chalmin, and C. Rebe, “Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape,” Journal of Biomedicine and Biotechnology, vol. 2012, Article ID 473712, 9 pages, 2012. View at Publisher · View at Google Scholar
  7. I. Feoktistov, S. Ryzhov, H. Zhong et al., “Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype,” Hypertension, vol. 44, no. 5, pp. 649–654, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Allard, M. Turcotte, K. Spring, S. Pommey, I. Royal, and J. Stagg, “Anti-CD73 therapy impairs tumor angiogenesis,” International Journal of Cancer, vol. 134, no. 6, pp. 1466–1473, 2014. View at Publisher · View at Google Scholar
  9. A. Ohta, E. Gorelik, S. J. Prasad et al., “A2A adenosine receptor protects tumors from antitumor T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 35, pp. 13132–13137, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. S. Longhi, S. C. Robson, S. H. Bernstein, S. Serra, and S. Deaglio, “Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states,” Journal of Molecular Medicine, vol. 91, no. 2, pp. 165–172, 2013. View at Publisher · View at Google Scholar
  11. S. C. Robson, J. Sévigny, and H. Zimmermann, “The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance,” Purinergic Signalling, vol. 2, no. 2, pp. 409–430, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. G. G. Yegutkin, “Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade,” Biochimica et Biophysica Acta, vol. 1783, no. 5, pp. 673–694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Zimmermann, M. Zebisch, and N. Sträter, “Cellular function and molecular structure of ecto-nucleotidases,” Purinergic Signalling, vol. 8, no. 3, pp. 437–502, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. H. K. Eltzschig, D. Köhler, T. Eckle, T. Kong, S. C. Robson, and S. P. Colgan, “Central role of Sp1-regulated CD39 in hypoxia/ischemia protection,” Blood, vol. 113, no. 1, pp. 224–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Stella, L. Bavaresco, E. Braganhol et al., “Differential ectonucleotidase expression in human bladder cancer cell lines,” Urologic Oncology, vol. 28, no. 3, pp. 260–267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. B. M. Künzli, M.-I. Bernlochner, S. Rath et al., “Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer,” Purinergic Signalling, vol. 7, no. 2, pp. 231–241, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. F. di Virgilio, “Purines, purinergic receptors, and cancer,” Cancer Research, vol. 72, no. 21, pp. 5441–5447, 2012. View at Publisher · View at Google Scholar
  18. J. Bastid, A. Cottalorda-Regairaz, G. Alberici, N. Bonnefoy, J. F. Eliaou, and A. Bensussan, “ENTPD1/CD39 is a promising therapeutic target in oncology,” Oncogene, vol. 32, no. 14, pp. 1743–1751, 2012. View at Publisher · View at Google Scholar
  19. J. Stagg, U. Divisekera, N. McLaughlin et al., “Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 4, pp. 1547–1552, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. B. Zhang, “Opportunities and challenges for anti-CD73 cancer therapy,” Immunotherapy, vol. 4, no. 9, pp. 861–865, 2012. View at Publisher · View at Google Scholar
  21. X. Matias-Guiu and J. Prat, “Molecular pathology of endometrial carcinoma,” Histopathology, vol. 62, no. 1, pp. 111–123, 2013. View at Publisher · View at Google Scholar
  22. E. Colas, C. Perez, S. Cabrera et al., “Molecular markers of endometrial carcinoma detected in uterine aspirates,” International Journal of Cancer, vol. 129, no. 10, pp. 2435–2444, 2011. View at Publisher · View at Google Scholar
  23. R. A. Soslow, “High-grade endometrial carcinomas—strategies for typing,” Histopathology, vol. 62, no. 1, pp. 89–110, 2013. View at Publisher · View at Google Scholar
  24. E. Aliagas, A. Vidal, B. Torrejon-Escribano et al., “Ecto-nucleotidases distribution in human cyclic and postmenopausic endometrium,” Purinergic Signalling, vol. 9, no. 2, pp. 227–237, 2013. View at Publisher · View at Google Scholar
  25. E. Aliagas, B. Torrejón-Escribano, E. G. Lavoie et al., “Changes in expression and activity levels of ecto-5′-nucleotidase/ CD73 along the mouse female estrous cycle,” Acta Physiologica, vol. 199, no. 2, pp. 191–197, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at Google Scholar · View at Scopus
  27. E. Aliagas, I. Villar-Menendez, J. Sevigny et al., “Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the ‘adenosine hypothesis’,” Purinergic Signalling, vol. 9, no. 4, pp. 599–608, 2013. View at Publisher · View at Google Scholar
  28. J. Stagg and M. J. Smyth, “Extracellular adenosine triphosphate and adenosine in cancer,” Oncogene, vol. 29, no. 39, pp. 5346–5358, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. V. S. Klimberg, K. C. Westbrook, and S. Korourian, “Use of touch preps for diagnosis and evaluation of surgical margins in breast cancer,” Annals of Surgical Oncology, vol. 5, no. 3, pp. 220–226, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. X. Li, X. Qi, L. Zhou et al., “Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells,” Gynecologic Oncology, vol. 106, no. 1, pp. 233–243, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Konstantinos, S. Marios, M. Anna, K. Nikolaos, P. Efstratios, and A. Paulina, “Expression of p53 in imprint smears of endometrial carcinoma,” Diagnostic Cytopathology, 2013. View at Publisher · View at Google Scholar
  32. G. Forte, R. Sorrentino, A. Montinaro et al., “Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma,” The Journal of Immunology, vol. 189, no. 5, pp. 2226–2233, 2013. View at Publisher · View at Google Scholar